What sector is TLSIW in?

Healthcare, in the Surgical Instruments industry.

NASDAQ · TLSIWHealthcareSurgical Instruments

TriSalus Life Sciences, Inc. Warrant (TLSIW)

$0.8099+1.24%

Close Sep 24, 2026 · split-adjusted

Sep 24, 2026$0.81▼ 56.22% in range

Sep 29, 2025Low $0.52 · High $1.85Sep 24, 2026

What changed · written from our data

As of Sep 28, 2026

TriSalus Life Sciences, Inc. Warrant closed at $0.81 on Sep 24, up 1.24%, 56.2% below its highest close since Aug 11. Volume of 3.0K shares was 0.65× its 20-day average (below normal).

Split-adjusted performance: -10.0% over one month, -19.0% over six months.

In the quarter ended Jun 30, 2026, revenue was $11.41M, up 1.7% from a year earlier, with a net margin of -80.5%.

Short interest was 17.9K shares at the Sep 15 settlement, up 10.0% from the prior report (350.9 days to cover).

Market cap—

Revenue · quarter$11.4M+1.7% YoY

Diluted EPS$-0.16—

P/E · TTM—

Net margin-80.5%Gross 86.8%

Dividend yieldNone

Range since Aug 110.52 – 1.85−56.2% from high

Volume3.0K0.65× 20-day avg

Volatility · 60d295.7%Annualised

Short % of float—350.9 days to cover

Net cash$13.2MCash $46.3M

Next earnings—Not scheduled

Split-adjusted performance

1W −8.0%1M −10.0%3M −4.7%6M −19.0%YTD −51.2%1Y —3Y +131.4%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 111 companies (100 = best)

6-month momentum—

Revenue growth—

Net margin—

Value (low P/E)—

Size—

Industry medians: 6-month return −4.4%, revenue growth +9.5%, net margin −9.2%, P/E 28.3×.

Short interest

Details →

Shares short17.9K+10.0% vs prior

Days to cover350.9Settled Sep 15

% of float—

Short vol. 10d57.3%of daily volume

News about TriSalus Life Sciences, Inc. Warrant

All news →

No recent articles focused on TriSalus Life Sciences, Inc. Warrant.

Quick answers

What does TriSalus Life Sciences, Inc. Warrant do?: TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery.
What sector is TLSIW in?: Healthcare, in the Surgical Instruments industry.

About TriSalus Life Sciences, Inc. Warrant

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

HQ: Westminster, CO102 employeesListed Aug 11, 2023trisaluslifesci.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology